REMUS Stock Overview
Engages in the marketing, trading, and distribution of pharmaceutical finished formulations and products in India and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Remus Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹2,626.25 |
| 52 Week High | ₹2,764.00 |
| 52 Week Low | ₹1,012.50 |
| Beta | 0 |
| 11 Month Change | 34.95% |
| 3 Month Change | 45.44% |
| 1 Year Change | 133.08% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 484.65% |
Recent News & Updates
Remus Pharmaceuticals Limited's (NSE:REMUS) P/E Is Still On The Mark Following 28% Share Price Bounce
Aug 20
Returns On Capital Signal Tricky Times Ahead For Remus Pharmaceuticals (NSE:REMUS)
Jun 27Recent updates
Remus Pharmaceuticals Limited's (NSE:REMUS) P/E Is Still On The Mark Following 28% Share Price Bounce
Aug 20Returns On Capital Signal Tricky Times Ahead For Remus Pharmaceuticals (NSE:REMUS)
Jun 27Concerns Surrounding Remus Pharmaceuticals' (NSE:REMUS) Performance
May 23Remus Pharmaceuticals Limited (NSE:REMUS) Looks Just Right With A 29% Price Jump
May 21Shareholder Returns
| REMUS | IN Healthcare | IN Market | |
|---|---|---|---|
| 7D | 6.8% | 1.8% | 1.8% |
| 1Y | 133.1% | 44.8% | 45.5% |
Return vs Industry: REMUS exceeded the Indian Healthcare industry which returned 44.8% over the past year.
Return vs Market: REMUS exceeded the Indian Market which returned 45.5% over the past year.
Price Volatility
| REMUS volatility | |
|---|---|
| REMUS Average Weekly Movement | 9.8% |
| Healthcare Industry Average Movement | 5.7% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in IN Market | 9.8% |
| 10% least volatile stocks in IN Market | 4.4% |
Stable Share Price: REMUS's share price has been volatile over the past 3 months.
Volatility Over Time: REMUS's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 38 | Arpit Shah | remuspharma.com |
Remus Pharmaceuticals Limited engages in the marketing, trading, and distribution of pharmaceutical finished formulations and products in India and internationally. It is involved in trading of active pharmaceutical ingredient, as well as provides technical consultancy services to various distributors and contract manufacturing services. The company offers capsule, cream, eye drop, gel, infusion, inhalation, inhaler, injection, nail lacquer, nasal solution, nasal spray, nebulizer, ointment, ophthalmic, oral gel, oral solution, oral suspension, sachet, suspension, and tablets.
Remus Pharmaceuticals Limited Fundamentals Summary
| REMUS fundamental statistics | |
|---|---|
| Market cap | ₹15.71b |
| Earnings (TTM) | ₹215.37m |
| Revenue (TTM) | ₹2.12b |
71.8x
P/E Ratio7.3x
P/S RatioIs REMUS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| REMUS income statement (TTM) | |
|---|---|
| Revenue | ₹2.12b |
| Cost of Revenue | ₹1.64b |
| Gross Profit | ₹481.73m |
| Other Expenses | ₹266.36m |
| Earnings | ₹215.37m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 36.55 |
| Gross Margin | 22.67% |
| Net Profit Margin | 10.14% |
| Debt/Equity Ratio | 11.1% |
How did REMUS perform over the long term?
See historical performance and comparison